专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007084290A2 COMPOSITIONS OF AN ANTICONVULSANT AND METHODS OF USING THE SAME FOR REVERSING WEIGHT GAIN 审中-公开
标题翻译：抗生素的组合物和使用相同方法反转重量增益
公开(公告)号：WO2007084290A2
公开(公告)日：2007-07-26
申请号：PCT/US2007/000576
申请日：2007-01-10
申请人： OREXIGEN THERAPEUTICS, INC. , MCKINNEY, Anthony, A. , TOLLEFSON, Gary , COWLEY, Michael, A.
发明人： MCKINNEY, Anthony, A. , TOLLEFSON, Gary , COWLEY, Michael, A.
IPC分类号： A61K31/135 , A61K31/423 , A61K31/498 , A61K31/5513
CPC分类号： A61K45/06 , A61K31/135 , A61K31/137 , A61K31/20 , A61K31/423 , A61K31/498 , A61K31/5513 , A61K31/554 , A61K33/00 , A61K2300/00
摘要： Disclosed are compositions for reversing weight gain comprising a first compound and a second compound, where the first compound is an anticonvulsant and the second compound is a psychotherapeutic agent.
摘要翻译：公开了用于逆转体重增加的组合物，其包含第一化合物和第二化合物，其中第一化合物是抗惊厥药，第二化合物是心理治疗剂。

2. 发明申请

WO2007067341A2 COMPOSITIONS AND METHODS FOR INCREASING INSULIN SENSITIVITY 审中-公开
标题翻译：用于增加胰岛素敏感性的组合物和方法
公开(公告)号：WO2007067341A2
公开(公告)日：2007-06-14
申请号：PCT/US2006/044966
申请日：2006-11-20
申请人： OREXIGEN THERAPEUTICS, INC. , COWLEY, Michael A. , MCKINNEY, Anthony A. , TOLLEFSON, Gary
发明人： COWLEY, Michael A. , MCKINNEY, Anthony A. , TOLLEFSON, Gary
IPC分类号： A61K31/00 , A61K31/135 , A61K31/138 , A61K31/423
CPC分类号： A61K38/28 , A61K31/135 , A61K31/137 , A61K31/138 , A61K31/35 , A61K31/357 , A61K31/423 , A61K31/445 , A61K31/4525 , A61K31/485 , A61K31/519 , A61K31/5415 , A61K31/55 , A61K31/551 , A61K31/5513 , A61K31/554 , A61K31/7048 , A61K45/06 , A61K2300/00
摘要： Methods and compositions for treating a blood glucose condition involve identifying a suitable subject and administering an effective amount of a composition that contains one or more of an opioid antagonist, an anticonvulsant, and a psychotherapeutic agent. The compositions can include insulin. In some embodiments, such methods and compositions can be used to modulate a blood glucose level. In preferred embodiments, such methods and compositions are useful for increasing a subject's sensitivity to insulin.
摘要翻译：用于治疗血糖状况的方法和组合物包括鉴定合适的受试者并施用有效量的含有阿片样物质拮抗剂，抗惊厥药和精神治疗药物中的一种或多种的组合物。组合物可以包括胰岛素。在一些实施方案中，这些方法和组合物可用于调节血糖水平。在优选的实施方案中，这些方法和组合物可用于增加受试者对胰岛素的敏感性。

3. 发明申请

WO2007016108A1 COMPOSITIONS FOR AFFECTING WEIGHT LOSS 审中-公开
标题翻译：影响重量损失的组合物
公开(公告)号：WO2007016108A1
公开(公告)日：2007-02-08
申请号：PCT/US2006/028875
申请日：2006-07-24
申请人： OREXIGEN THERAPEUTICS, INC. , TOLLEFSON, Gary , MCKINNEY, Anthony, A. , HIGGIN, Michelle, S. , MCCALL, John, M.
发明人： TOLLEFSON, Gary , MCKINNEY, Anthony, A. , HIGGIN, Michelle, S. , MCCALL, John, M.
IPC分类号： A61K45/06 , A61K31/485 , A61K31/137 , A61K31/138 , A61P3/04
CPC分类号： A61K31/137 , A61K31/138 , A61K31/165 , A61K31/485 , A61K45/06 , A61K2300/00
摘要： Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is a metabolite of naltrexone, such as 6-β-naltrexol or a prodrug of a naltrexone metabolite, and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) and/or a melanocortin 4 receptor (MC4-R), and/or increases the concentration of α-MSH in the central nervous system. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity with a metabolite of naltrexone, such as 6-β-naltrexol or a prodrug of a naltrexone metabolite, and treating that individual to enhance α-MSH activity, e.g., by administration of a second compound causes increased agonism of MC3-R and/or MC4-R, and/or increases the concentration of α-MSH in the central nervous system.
摘要翻译：公开了用于影响体重减轻的组合物，其包含第一化合物和第二化合物，其中第一化合物是纳曲酮的代谢物，例如6-β-纳曲醇或纳曲酮代谢物的前药，以及第二化合物引起黑皮质素3受体（MC3-R）和/或黑皮质素4受体（MC4-R）的激动作用增加，和/或增加中枢神经系统中α-MSH的浓度。还公开了影响体重减轻，增加能量消耗，增加个体饱腹感或抑制个体食欲的方法，包括鉴定需要其的个体并治疗该个体以拮抗纳曲酮代谢物的阿片样物质受体活性，例如作为6-β-纳曲醇或纳曲酮代谢物的前药，并且治疗该个体以增强α-MSH活性，例如通过施用第二化合物引起MC3-R和/或MC4-R增加的激动作用，和/或增加中枢神经系统中α-MSH的浓度。

4. 发明申请

WO2006130522A2 METHODS AND COMPOSITIONS FOR MANAGING PSYCHOTIC DISORDERS 审中-公开
标题翻译：管理心理障碍的方法和组成
公开(公告)号：WO2006130522A2
公开(公告)日：2006-12-07
申请号：PCT/US2006/020616
申请日：2006-05-25
申请人： OREXIGEN THERAPEUTICS, INC. , TOLLEFSON, Gary
发明人： TOLLEFSON, Gary
IPC分类号： A61K31/496 , A61K31/551 , A61K31/519 , A61K31/423
CPC分类号： A61K31/519 , A61K31/19 , A61K31/423 , A61K31/425 , A61K31/496 , A61K31/551 , A61K31/7008 , A61K31/7048 , A61K2300/00
摘要： Compositions for treating psychotic disorders comprise a first ingredient and a second ingredient, wherein the first ingredient comprises at least one antipsychotic agent selected from the group consisting of ziprasidone, olanzapine and risperidone and the second ingredient comprises at least one anticonvulsant selected from the group consisting of zonisamide and topiramate. Methods of treating psychotic disorders, symptoms associated with psychotic disorders, and side effects associated with antipsychotic agents, comprise administering a first ingredient and a second ingredient, wherein the first ingredient comprises at least one antipsychotic agent selected from the group consisting of ziprasidone, olanzapine and risperidone and the second ingredient comprises at least one anticonvulsant selected from the group consisting of zonisamide and topiramate. The second ingredient of the compositions and methods may further comprise an antidepressant. In various embodiments, the antipsychotic agent and the anticonvulsant act synergistically to alleviate symptoms and/or side effects associated with psychotic disorders and their treatment.
摘要翻译：用于治疗精神病的组合物包含第一成分和第二成分，其中第一成分包含至少一种选自齐拉西酮，奥氮平和利培酮的抗精神病药，第二成分包含至少一种选自以下的抗惊厥药：唑尼沙胺和托吡酯。治疗精神病，与精神病性症状相关的症状以及与抗精神病药相关的副作用的方法包括施用第一成分和第二成分，其中第一成分包含至少一种抗精神病药，其选自齐拉西酮，奥氮平和利培酮和第二成分包含至少一种选自唑尼沙胺和托吡酯的抗惊厥药。组合物和方法的第二成分可以进一步包含抗抑郁药。在各种实施方案中，抗精神病药和抗惊厥剂协同作用以缓解与精神病性疾病及其治疗相关的症状和/或副作用。

5. 发明申请

WO2015085044A1 COMPOSITIONS AND METHODS FOR REDUCING MAJOR ADVERSE CARDIOVASCULAR EVENTS 审中-公开
标题翻译：用于减少主要不良心血管事件的组合物和方法
公开(公告)号：WO2015085044A1
公开(公告)日：2015-06-11
申请号：PCT/US2014/068527
申请日：2014-12-04
申请人： OREXIGEN THERAPEUTICS, INC.
发明人： KLASSEN, Preston , TAYLOR, Kristin
IPC分类号： A61K31/485 , A61K31/137 , A61P3/04
CPC分类号： A61K31/485 , A61K31/137 , A61K2300/00
摘要： The present application relates to compositions, kits, uses, systems and methods of using naltrexone and bupropion, or pharmaceutically acceptable salts thereof, for reducing the risk of adverse cardiovascular outcomes or events, including Major Adverse Cardiovascular Events (MACE) in subjects, preferably those at increased risk of adverse cardiovascular outcomes or MACE, that may be overweight or obese. The present application also relates to compositions, kits, uses, systems and methods of using naltrexone and bupropion or pharmaceutically acceptable salts thereof for treatment of overweight or obesity in subjects, preferably at increased risk of adverse cardiovascular outcomes or MACE, wherein the treatment reduces the risk of MACE.
摘要翻译：本申请涉及使用纳曲酮和安非他酮或其药学上可接受的盐的组合物，试剂盒，用途，系统和方法，用于降低不良心血管结局或事件的风险，包括受试者中的主要不良心血管事件（MACE），优选那些心血管事件不良或MACE的风险增加，可能超重或肥胖。本申请还涉及将纳曲酮和安非他酮或其药学上可接受的盐用于治疗受试者的超重或肥胖的组合物，试剂盒，用途，系统和方法，优选地具有不良心血管结局或MACE的增加的风险，其中治疗减少 MACE的风险。

6. 发明申请

WO2007145863A3 SUSTAINED RELEASE FORMULATION OF NALTREXONE 审中-公开
公开(公告)号：WO2007145863A3
公开(公告)日：2007-12-21
申请号：PCT/US2007/013030
申请日：2007-05-31
申请人： OREXIGEN THERAPEUTICS, INC. , MCKINNEY, Anthony A. , TOLLEFSON, Gary D. , SOLTERO, Richard , DUNZO, Thea Elise
发明人： MCKINNEY, Anthony A. , TOLLEFSON, Gary D. , SOLTERO, Richard , DUNZO, Thea Elise
IPC分类号： A61K31/135 , A61K31/137 , A61K31/485 , A61K9/20
摘要： A sustained-release oral dosage form of naltrexone or a pharmaceutically acceptable salt thereof is provided. The oral dosage form may be administered with another compound. Administration of the oral dosage form may reduce a side effect, which may be a side effect at least partially attributable to a weight-loss treatment. The oral dosage form may be administered to treat a weight-loss condition.

7. 发明申请

WO2007047351A3 METHODS FOR TREATING HYPERTENSION IN OVERWEIGHT AND OBESE INDIVIDUALS 审中-公开
标题翻译：治疗高血压和肥胖个体的方法
公开(公告)号：WO2007047351A3
公开(公告)日：2007-11-01
申请号：PCT/US2006039862
申请日：2006-10-13
申请人： OREXIGEN THERAPEUTICS INC , GADDE KISHORE M , KRISHNAN K RANGA R , MCKINNEY ANTHONY
发明人： GADDE KISHORE M , KRISHNAN K RANGA R , MCKINNEY ANTHONY
IPC分类号： C07D235/02 , C07D403/02
CPC分类号： A61K31/485 , A61K45/06 , A61K2300/00
摘要： Disclosed are novel compositions for treating hypertension and conditions associated with hypertension comprising a first ingredient and a second ingredient, wherein the first ingredient comprises at least one anti-hypertensive agent and the second ingredient comprises at least one anti-obesity agent. Also disclosed are methods of treating hypertension and conditions associated with hypertension comprising administering a first ingredient and a second ingredient, wherein the first ingredient comprises at least one anti-hypertensive agent and the second ingredient comprises at least one anti-obesity agent. In various embodiments, the combinations act synergistically to alleviate symptoms and/or risk factors associated with hypertension. In preferred embodiments, the anti-obesity agent does not substantially affect blood pressure, and thereby decreases the risk and/or unpredictability associated with concurrent administration of the anti-hypertensive agent.
摘要翻译：公开了用于治疗高血压和与高血压相关的病症的新型组合物，其包含第一成分和第二成分，其中第一成分包含至少一种抗高血压药，第二成分包含至少一种抗肥胖剂。还公开了治疗高血压和与高血压相关的病症的方法，包括施用第一成分和第二成分，其中第一成分包含至少一种抗高血压药，第二成分包含至少一种抗肥胖剂。在各种实施方案中，组合起协同作用以缓解与高血压相关的症状和/或危险因素。在优选的实施方案中，抗肥胖剂基本上不影响血压，从而降低与同时施用抗高血压剂相关的风险和/或不可预测性。

8. 发明申请

WO2006088748A2 METHOD FOR TREATING OBESITY 审中-公开
标题翻译：治疗肥胖的方法
公开(公告)号：WO2006088748A2
公开(公告)日：2006-08-24
申请号：PCT/US2006/004836
申请日：2006-02-13
申请人： OREXIGEN THERAPEUTICS, INC. , GADDE, Kishore, M. , KRISHNAN, Ranga, R., K.
发明人： GADDE, Kishore, M. , KRISHNAN, Ranga, R., K.
IPC分类号： A61K31/423 , A61K31/5375 , A61P3/04 , A61P9/12 , A61P3/10
CPC分类号： A61K31/423 , A61K31/12 , A61K31/135 , A61K31/255 , A61K31/35 , A61K31/357 , A61K31/42 , A61K31/5375 , A61K31/7024 , A61K45/06 , A61K2300/00
摘要： The present invention relates generally to methods of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight loss-promoting anticonvulsant either alone or in combination with bupropion or metabolites thereof or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.
摘要翻译：本发明一般涉及使用例如单独或与安非他酮或其代谢物或增强去甲肾上腺素的活性的其他化合物的唑尼沙胺或其它减肥促进抗惊厥药相关联的治疗肥胖症并最小化代谢危险因素的方法，以及 /或多巴胺通过吸收抑制或其他机制。

9. 发明申请

WO2011085331A1 METHODS OF PROVIDING WEIGHT LOSS THERAPY IN PATIENTS WITH MAJOR DEPRESSION 审中-公开
标题翻译：在主要患者中提供重量损失治疗的方法DEPRESSION
公开(公告)号：WO2011085331A1
公开(公告)日：2011-07-14
申请号：PCT/US2011/020712
申请日：2011-01-10
申请人： OREXIGEN THERAPEUTICS, INC. , DUNAYEVICH, Eduardo
发明人： DUNAYEVICH, Eduardo
IPC分类号： A01N43/42 , A61K31/44
CPC分类号： A61K31/485 , A61K9/0053 , A61K31/137 , A61K31/439 , Y10S514/909 , Y10S514/91 , A61K2300/00
摘要： Disclosed are methods of providing weight loss therapy, particularly for patients suffering from major depression.
摘要翻译：公开了提供减肥治疗的方法，特别是对于患有重度抑郁症的患者。

10. 发明申请

WO2008060963A3 LAYERED PHARMACEUTICAL FORMULATIONS COMPRISING AN INTERMEDIATE RAPIDLY DISSOLVING LAYER 审中-公开
标题翻译：包含中间快速溶解层的分层药物制剂
公开(公告)号：WO2008060963A3
公开(公告)日：2008-07-10
申请号：PCT/US2007084177
申请日：2007-11-08
申请人： OREXIGEN THERAPEUTICS INC , MCKINNEY ANTHONY A , TOLLEFSON GARY , WEBER ECKARD , SOLTERO RICK
发明人： MCKINNEY ANTHONY A , TOLLEFSON GARY , WEBER ECKARD , SOLTERO RICK
IPC分类号： A61K9/24 , A61K31/137 , A61K31/138 , A61K31/155 , A61K31/35 , A61K31/423 , A61K31/485 , A61K31/5513
CPC分类号： A61K9/209 , A61K9/0002 , A61K9/2018 , A61K9/2054 , A61K31/137 , A61K31/138 , A61K31/155 , A61K31/35 , A61K31/357 , A61K31/42 , A61K31/423 , A61K31/485 , A61K31/551 , A61K31/5513 , A61K45/06 , A61K47/26 , A61K2300/00
摘要： In one embodiment a layered pharmaceutical formulation includes two or more pharmaceutical layers and an intermediate layer disposed between at least two of the two or more pharmaceutical layers, the intermediate layer configured to dissolve in vivo to thereby leave the two or more pharmaceutical layers substantially intact. In one embodiment, an active pharmaceutical ingredient in at least one of the pharmaceutical layers is selected from bupropion, zonisamide, naltrexone, topiramate, phentermine, metformin, olanzapine and fluoxetine.
摘要翻译：在一个实施方案中，分层药物制剂包含两个或更多个药物层和设置在两个或更多个药物层中的至少两个之间的中间层，所述中间层被配置为在体内溶解，从而使两个或更多个药物层基本上保持完好。在一个实施方案中，至少一个药物层中的活性药物成分选自安非他酮，唑尼沙胺，纳曲酮，托吡酯，芬特明，二甲双胍，奥氮平和氟西汀。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式